(NasdaqGM:STRR),(NasdaqGM:STRRP), Q2 2025 revenues increased ~76% to $23.7 million and gross profit increased ~182% to $6.3 million Generated Adjusted EBITDA of $7.0 million Quarter-end Building Solutions backlog stands at $25.7 million OLD GREENWICH, Conn., Aug. 13, 2025 (GLOBE NEWSWIRE) — Star Equity Holdings, Inc. (Nasdaq: STRR; STRRP) (“Star” or the “Company”), a diversified holding company, […]

(NYSE:FCN), WASHINGTON, Aug. 13, 2025 (GLOBE NEWSWIRE) — FTI Consulting, Inc. (NYSE: FCN) today announced that professionals from its Compass Lexecon subsidiary topped the Lexology Index: Competition 2025 list for global economic consulting firms, with 66 professionals named. In addition, six FTI Consulting professionals were named to the list. The following Compass Lexecon and FTI

TAMPA, FLORIDA / ACCESS Newswire / August 13, 2025 / Wellgistics Health, Inc. (NASDAQ:WGRX) ("Wellgistics Health" or the "Company"), a leader in next-generation pharmaceutical distribution, digital prescription routing, and AI-powered hub fulfillment, today announced the launch of its Ripple Labs-powered XRP Implementation Program, giving independent pharmacies access to blockchain-based payments in the prescription drug space

Transaction reinforces Protos' position as North America's leading tech-enabled managed services provider, delivering integrated protection solutions to clients seeking a modern, data-driven security experience Protos Security, the leading national tech-enabled managed services provider delivering integrated protection solutions across North America, announces the successful divestiture of Mulligan Security (including MG Security Services) to Allied Universal. The

MCAP Inc. (OTC: MCAP), a financial technology and securities market making company, today reported second quarter 2025 earnings of $0.28 per share. Quarterly total revenue was $33mm, a 45% YoY increase, resulting in quarterly EBITDA of $9.5mm. https://mma.prnewswire.com/media/1995325/MCAP_Logo.jpg MCAP continues to expand through its investment in customer relationships, application software development, securities execution platforms and

Performance-based equity program align leadership rewards with treasury growth and market capitalization milestones https://mma.prnewswire.com/media/2718414/Unitronix_Logo.jpg Unitronix Corp. (OTC: UTRX) (“Unitronix” or the “Company”), a blockchain company focused on real-world asset (RWA) tokenization and cryptocurrency asset management, today announced the adoption of a Milestone-Based Stock Option Program for its CEO, select advisers, and key insiders. The program

— Firm hires Senior Portfolio Manager to support trading operations Extant Capital (“Extant” or “the Firm”), an alternative asset manager focused on absolute return investing in credit markets, today announced it received a $200 million cornerstone investment from New Holland Capital, LLC (“New Holland”) and will begin trading this month. The investment will provide Extant

Policy changes and a shifting economic climate can, and often do, have far-reaching effects on estate planning and related considerations. Economic downturns and changes to tax laws can significantly influence the value of assets, the structure of wealth transfers, and the strategies individuals and families employ to preserve their legacies.Tannenbaum Helpern's Trusts and Estates practice

FINN Partners, a leading global integrated marketing and communications agency, has appointed Sophie Taylor-Roberts as Managing Partner and UK Health Group Lead. Taylor-Roberts will lead the FINN UK Health Group in strengthening its reputation as a leading communications partner for the biopharma, medical device and health system sectors. She succeeds Julie Adrian, who returned to

PANTHERx® Rare Pharmacy, a leader in rare disease product patient access and support services inthe United States, announced that it was selected by Insmed as part of the network of specialty pharmacies to dispenseBRINSUPRI™ (brensocatib), a once daily oral medication to treat non-cystic fibrosis bronchiectasis (NCFB) in adults and pediatric patients 12 years and older.1